• Pierre Demolis (Oncology Working Party, EMA, NL)
• Paul Kluetz (FDA, US)
• Francesco de Lorenzo (European Cancer Patient Coalition, IT)
• Elisabeth Piault-Louis (Genentech, FR)
• Margarida Oliveira (INFARMED, PT)
• Rosanne Janssens (KU Leuven, BE)

SESSION 2

• FDA Secondary Analyses of Submitted PRO Assessment Strategies and Data – Belinda King-Kallimanis (FDA, US)
• CASE STUDY: Pancreas Carcinoma – Natalija Frank (Medical University of Vienna, AT)
• CASE STUDY: Patients Feedback into Oncology Drug Development through Patient Advisory Board Meetings – Tanja Keiper / Claudia Hey (Merck Healthcare KGaA, DE)
• CASE STUDY: Rituxan Hycela – Case Study for Preference with Mode of Administration – Elisabeth Piault-Louis (Genentech, FR)

SESSION 3

• How FDA is Using Patient Experience Data in the Determination of Risk and Benefit – Bellinda King-Kallimanis (FDA, US)
• Patient Involvement in Benefit/Risk Discussions at EMA – Nathalie Bere (EMA, NL)
• Patient Involvement in HTA in Portugal – a Part of the INCLUIR Project – Margarida Oliveira (INFARMED, PT)

SESSION 4

• Patient Involvement in Preference Studies: a Case Study in Multiple Myeloma – Rosanne Janssens (KU Leuven, BE) & Nicole Wicki (Myeloma Patients Europe, BE)

SESSION 5

• What is Next for Patient Preference Studies in Cancer Drug Development? : An Overview, Challenges & Opportunities – Vikas Soekhai (Erasmus University Rotterdam) & Samare Huls (Erasmus University Rotterdam)